ALL |
acute lymphoblastic leukemia |
AML |
acute myeloid leukemia |
CNS |
central nervous system |
CoALL |
cooperative study group for childhood acute lymphoblastic
leukemia |
CPM |
cyclophosphamide |
CTCAE |
common terminology criteria for adverse events |
EOI |
end of induction |
IGH |
immunoglobulin heavy chain |
HR |
high-risk |
HR-I |
high-risk intensified |
HR-IF |
high-risk induction failure |
HSCT |
hematopoietic stem cell transplantation |
IF |
induction failure |
LR |
low-risk |
MRD |
minimal residual disease |
MTX |
methotrexate |
n.q. |
non quantifiable |
pOS |
probability of overall survival |
pEFS |
probability of event-free survival |
PEG-ASP |
pegylated asparaginase |
SAE |
severe adverse event |
SE |
standard error |
TCR |
T cell receptor |